clinical trial · NCT07214727
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
Alzheimer's DiseaseALN-5288Placebo
brief summary
The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
started
Oct 15, 2025
primary completion
Mar 6, 2030
completion
Mar 6, 2030
last updated
Jun 12, 2026
official title
A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol